about
sameAs
Cellular and viral determinants of retroviral nuclear entryBioinformatic analysis of HIV-1 entry and pathogenesis.HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 useSCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivoDefining the fitness of HIV-1 isolates with dual/mixed co-receptor usageMolecular dynamics simulations on SDF-1alpha: binding with CXCR4 receptorBroadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes.Multiple active states and oligomerization of CCR5 revealed by functional properties of monoclonal antibodies.Successful identification of novel agents to control infectious diseases from screening mixture-based peptide combinatorial libraries in complex cell-based bioassays.Human immunodeficiency virus type 1 entry inhibitors selected on living cells from a library of phage chemokines.Identifying interaction sites in "recalcitrant" proteins: predicted protein and RNA binding sites in rev proteins of HIV-1 and EIAV agree with experimental dataThe capsid protein of human immunodeficiency virus: designing inhibitors of capsid assembly.The cellular HIV-1 Rev cofactor hRIP is required for viral replication.Analysis of human immunodeficiency virus type 1 reverse transcriptase subunit structure/function in the context of infectious virions and human target cells.Analysis of binding sites for the new small-molecule CCR5 antagonist TAK-220 on human CCR5.HIV chemotherapy.Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate.Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.Targeted delivery of PSC-RANTES for HIV-1 prevention using biodegradable nanoparticles.The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C.Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry.Inhibition of human immunodeficiency virus type 1 Env-mediated fusion by DC-SIGN.Targeting therapeutics to an exposed and conserved binding element of the HIV-1 fusion protein.Coreceptor usage and biological phenotypes of HIV-1 isolates.Inhibitory activity of 9-phenylcyclohepta[d]pyrimidinedione derivatives against different strains of HIV-1 as non-nucleoside reverse transcriptase inhibitors.Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages.Development of topical microbicides for prevention of human immunodeficiency virus and herpes simplex virus.Role of the human immunodeficiency virus type 1 envelope gene in viral fitness.Dissecting HIV-1 through RNA interference.Human immunodeficiency virus infection of the brain: pitfalls in evaluating infected/affected cell populations.Human genes that limit AIDS.Protein grafting of an HIV-1-inhibiting epitopeThe entry of entry inhibitors: a fusion of science and medicine.Antiviral activity and in vitro mutation development pathways of MK-6186, a novel nonnucleoside reverse transcriptase inhibitorThe discovery of a class of novel HIV-1 maturation inhibitors and their potential in the therapy of HIV.Delineating CD4 dependency of HIV-1: Adaptation to infect low level CD4 expressing target cells widens cellular tropism but severely impacts on envelope functionality.Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection.Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor.Identification of HIV inhibitors guided by free energy perturbation calculations.Targeting structural flexibility in HIV-1 protease inhibitor binding.
P2860
Q26778299-900CECDB-2295-49F1-9CE1-8FBC63588D51Q27693321-47108E96-B521-41E6-B2F3-8C1E555B6ED0Q28344746-F0231EE0-7226-42B8-958E-14E86F48225DQ28362194-6AA43772-79F1-4DE0-A7D2-6B1F6F60C1BBQ30278577-8079360C-3BCE-47F4-A676-4B4DD1485138Q30332403-58E93517-5271-4E89-B2B0-E323F9E88F04Q30706865-E0E5109D-C463-4926-855D-55BB0D5E2BF9Q30857101-DB68CB55-BBDD-4ABA-9D5C-C8D0D5561D54Q30937880-38684ED0-ABD2-4F12-8D14-AF1C29DCAB1AQ30938337-9FAF26E2-09DB-4A9B-A6D0-38261F83F0ADQ31075700-D8B8F8A1-F254-4EF2-B0B8-B29582570346Q33510254-F2A777F8-AAF4-4960-9429-9EA2271C67FEQ33926825-B2A1B310-67C7-44B4-8D28-7C4633B55960Q33935269-86AF6A72-4CE2-4309-8BC7-2F6D2CD2894CQ34123627-447CE173-511F-421C-864A-8794524FE6D8Q34223088-CF700626-C608-4DCD-B3C3-4FACA1E9A396Q34340428-0C251B83-BDCF-4BF6-8A7A-BEDFEE5502F8Q34361680-DC357B59-6085-4098-B8C5-3151F0F67DE2Q34568549-CBDA7D79-CD61-4938-9936-475BA03345F5Q34781878-70855B36-D370-4DC1-BDF5-1807F5879811Q34975941-6A9E2C16-5CA2-4CCE-912C-33EB822BDAE7Q34976132-29402D45-FA05-4E6F-9C1B-3ACF57678F4EQ34981730-9F136F6F-D834-4E08-9202-B9170DD85C8DQ34999203-BB668067-E001-470B-98FD-86C121166A57Q35063966-83770BF4-608E-4A04-9AC3-FC2FD836071DQ35149275-529CA4C7-4B44-4776-B8A2-96264F5E73CAQ35175233-DABC7D1A-9CC0-4646-A3C7-98FBBC0AE35AQ35182388-87F3841B-DACC-439A-B6A1-2CFCCA947779Q35559168-8B6C44E3-D275-4664-A9B8-2C2037B7D892Q35681073-CA3E833C-5EEC-417D-82BF-6F5B30904517Q35787248-73ED424B-EC59-4CD9-8112-EF60D398AEE9Q35813478-99C639DD-CFBC-4D29-AEF0-867DDBE15385Q35976966-34D72E02-75A3-4EA4-BF43-B0FB6E316240Q36018893-90A26D52-5883-4434-A4C7-2CF98A80FC93Q36187060-8ADFBA68-96CC-42D2-BB58-A445BD13F97CQ36298503-A5FB5199-9FFF-444F-BEFE-3B329664F4FFQ36371505-AB728AA4-8188-4A78-8A76-CAB6A6FBE450Q36509765-70705515-8F1B-4833-A5EA-A812D60B9DA5Q36708826-E4F3E9DA-395D-4F8F-A3FC-9DD05D672766Q36727191-928FEAF1-6915-475E-A003-902BD55E9803
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
New targets for inhibitors of HIV-1 replication
@ast
New targets for inhibitors of HIV-1 replication
@en
New targets for inhibitors of HIV-1 replication
@nl
type
label
New targets for inhibitors of HIV-1 replication
@ast
New targets for inhibitors of HIV-1 replication
@en
New targets for inhibitors of HIV-1 replication
@nl
prefLabel
New targets for inhibitors of HIV-1 replication
@ast
New targets for inhibitors of HIV-1 replication
@en
New targets for inhibitors of HIV-1 replication
@nl
P356
P1476
New targets for inhibitors of HIV-1 replication
@en
P2093
M Stevenson
P2888
P356
10.1038/35036060
P407
P577
2000-10-01T00:00:00Z
P6179
1036373977